Autopsy report · NCT03610230

Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients

“Difficult patient recruitment due to COVID-19 epidemic”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

The University of Hong Kong

Sponsor type

University, hospital or other

Conditions

Iron Deficiency Anemia Treatment

Interventions

Iron Isomaltoside; Iron sucrose

Participants

16

Sites

1

Countries

Hong Kong

Trials that died the same way

• A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
  “Difficulty with patient recruitment due to COVID-19” (94% match in meaning)
• Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow
  “Covid 19 and difficulty with recruitment” (85% match in meaning)
• Pathology and Imaging in Kidney Allografts
  “recruitment difficulties due to impact of COVID-19 pandemic” (84% match in meaning)
• Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
  “COVID-19 challenges to recruitment” (83% match in meaning)
• Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
  “challenges in recruitment due to covid-19” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.